[Stages of grief in diabetes and metabolic control]. / Etapas del duelo en diabetes y control metabólico.

BACKGROUND: To identify type 2 diabetic patients, the stages of grief and its association with metabolic control. METHODS: 186 patients both sexes, without recent loss of a loved one or a terminal illness. We applied a previously validated instrument, which explored the stages of grief (denial, anger/disbelief, bargaining, depression, and acceptance). There was measured BMI, waist circumference, and 6-month averages of glucose, cholesterol and triglycerides. RESULTS: The associations between the stages of grief and clinical variables showed that BMI is greater denial 33.1 ± 6.2 vs 28.9 ± 4.6 33.1 with p = 0.001, in disbelief stage glucose is greater 190 ± 67 vs 167 ± 51 with p < 0.05. The negotiation phase is associated with older age, 65.6 ± 10 vs 59.1 ± 11 years with p = 0.001 and higher cholesterol level against 229.4 ± 39.1 vs 206.6 ± 40 with p < 0.05. The stage of depression was associated with increased diagnostic time vs. 13.3 ± 8.9 vs 9.4 ± 7.1 years with p < 0.05 and the blood glucose level 198.9 ± 60, vs 164 ± 51 mg/dL p = 0.001. CONCLUSIONS: There are logical associations between clinical variables and stages of grief. Identify the stages of grief, as an additional element in the evaluation of patients with diabetes will develop strategies to improve adherence to medical management and metabolic control.

Introducción: el objetivo de este artículo es identificar las etapas del duelo y su asociación con el control metabólico en pacientes diabéticos tipo 2. Métodos: se incluyeron 186 sujetos diabéticos, de ambos sexos, sin pérdida reciente de un ser querido ni enfermedades terminales. Se les aplicó un instrumento validado que exploró las etapas del duelo (negación, ira/incredulidad, negociación, depresión, y aceptación). Se midió: IMC, perímetro de cintura, niveles promedio de glucosa, colesterol y triglicéridos en los últimos 6 meses. Resultados: las asociaciones entre las etapas del duelo y las variables clínicas mostraron que en la negación, el IMC es mayor 33.1 ± 6.2 contra 28.9 ± 4.6 con p = 0.001; en etapa de incredulidad, la glucemia es mayor 190 ± 67 frente a 16 ± 51 con p < 0.05; la etapa de negociación se asocia a mayor edad 65.6 ± 10 contra 59.1 ± 11 años con p = 0.001 y con nivel de colesterol mayor de 229.4 ± 39.1 frente a 206.6 ± 40 con p < 0.05; la etapa de depresión se asoció con mayor tiempo de diagnóstico 13.3 ± 8.9 frente a 9.4 ± 7.1 años, con p < 0.05 y con el nivel de glucemia de 198.9 ± 60 frente a 164 ± 51 mg/dL con p = 0.001. Conclusiones: existen asociaciones lógicas entre variables clínicas y etapas del duelo. Se debe identificar el duelo como un elemento adicional en la evaluación de pacientes con diabetes y establecer estrategias que mejoren la adherencia al tratamiento y el control metabólico.

[Life style and metabolic control in DiabetIMSS program]. / Estilo de vida y control metabólico en diabéticos del programa DiabetIMSS.

OBJECTIVE: To compare the lifestyle and metabolic control of diabetes patients included and not included in the DiabetIMSS program. METHODS: Subjects with diabetes in the DiabetIMSS program and the general clinic were divided into three groups: group 1 first attended the program, group 2 were enrolled during the study, and group 3 had not been included the program. Demographic and clinical aspects were measured and the IMEVID instrument was applied. RESULTS: We included 539 type-2 diabetes patients, predominantly females (73.3%), mainly of primary school level, and more frequently on double-drug therapy. There were clinical differences between the three groups for program leavers in terms of weight, waist, blood pressure, fasting glucose, HbA1c, triglycerides, and IMEVID qualification, all p < 0.05; correlation analysis of the variables with the qualification of IMEVID was significant at p < 0.05. The higher number of variable control targets was for leavers (71% of group); those who were enrolled in the study was 32%, and who had not was 17.2%. CONCLUSIONS: There are significant differences in lifestyle and control target parameters in subjects who completed the DiabetIMSS program.